The cortex is the outer layer of the brain in which critical cognitive functions such as memory, language and perception take place. Interestingly, the findings also suggest that stopping smoking helps to restore at least part of the cortex’s thickness.
The study involved 244 male and 260 female subjects-five times larger than any previous similar research on smoking and cortical thickness. Their average age was 73. The test group included current smokers, ex-smokers and non-smokers. All of the subjects were examined as children in 1947 as part of the Scottish Mental Survey. Researchers used health data gathered during recent personal interviews with the subjects, and also analyzed data from MRI scans showing the current state of the subjects’ brain cortices.
“We found that current and ex-smokers had, at age 73, many areas of thinner brain cortex than those that never smoked. Subjects who stopped smoking seem to partially recover their cortical thickness for each year without smoking,” says the study’s lead author Dr. Sherif Karama, assistant professor of psychiatry at McGill University, psychiatrist at the Douglas Mental Health University Institute and an affiliate of the Montreal Neurological Institute. The apparent recovery process is slow, however, and incomplete. Heavy ex-smokers in the study who had given up smoking for more than 25 years still had a thinner cortex.
Although the cortex grows thinner with normal aging, the study found that smoking appears to accelerate the thinning process. A thinner brain cortex is associated with adult cognitive decline.
“Smokers should be informed that cigarettes could hasten the thinning of the brain’s cortex, which could lead to cognitive deterioration. Cortical thinning seems to persist for many years after someone stops smoking,” says Dr. Karama.
The study was conducted at the Montreal Neurological Institute McGill University and the University of Edinburgh’s Centre for Cognitive Ageing and Cognitive Epidemiology. Other participating institutions included the McGill University Health Centre, The Douglas Mental Health University Institute and Alzheimer Scotland Dementia Research Centre.
This study is published online today (February 10) in Molecular Psychiatry: http://www.nature.com/mp/journal/vaop/ncurrent/full/mp2014187a.html
The Montreal Neurological Institute and Hospital — The Neuro, is a unique academic medical centre dedicated to neuroscience. Founded in 1934 by the renowned Dr. Wilder Penfield, The Neuro is recognized internationally for integrating research, compassionate patient care and advanced training, all key to advances in science and medicine. The Neuro is a research and teaching institute of McGill University and forms the basis for the Neuroscience Mission of the McGill University Health Centre. Neuro researchers are world leaders in cellular and molecular neuroscience, brain imaging, cognitive neuroscience and the study and treatment of epilepsy, multiple sclerosis and neuromuscular disorders. For more information, visit www.mcgill.ca/neuro